Hartaj Singh
Stock Analyst
(2.26)
# 3,094
Out of 4,648 analysts
103
Total ratings
46.15%
Success rate
-5.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $376.58 | +59.33% | 7 | Oct 31, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $550 → $540 | $471.45 | +14.54% | 16 | Oct 30, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $54.02 | - | 8 | Sep 13, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $25 → $26 | $11.39 | +128.27% | 5 | Aug 13, 2024 | |
| SPRB Spruce Biosciences | Maintains: Outperform | $4 → $3 | $0.53 | +465.40% | 5 | Jun 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $1.82 | +449.45% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $9.01 | +565.93% | 5 | May 30, 2024 | |
| VIRX Viracta Therapeutics | Maintains: Outperform | $13 → $11 | $0.19 | +5,826.72% | 3 | May 23, 2024 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $180 | $122.68 | +46.72% | 9 | May 14, 2024 | |
| GANX Gain Therapeutics | Maintains: Outperform | $9 | $2.23 | +303.59% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 | $90.56 | +15.95% | 12 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $5.58 | +617.49% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $17.64 | +24.75% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $16 | $4.28 | +273.83% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $950 → $1,050 | $841.88 | +24.72% | 11 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.49 | - | 3 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $1.16 | +56,177.06% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $20.10 | +49.25% | 1 | Jan 26, 2018 |
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $376.58
Upside: +59.33%
Vertex Pharmaceuticals
Oct 30, 2024
Maintains: Outperform
Price Target: $550 → $540
Current: $471.45
Upside: +14.54%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $54.02
Upside: -
Astria Therapeutics
Aug 13, 2024
Maintains: Outperform
Price Target: $25 → $26
Current: $11.39
Upside: +128.27%
Spruce Biosciences
Jun 13, 2024
Maintains: Outperform
Price Target: $4 → $3
Current: $0.53
Upside: +465.40%
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $1.82
Upside: +449.45%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $9.01
Upside: +565.93%
Viracta Therapeutics
May 23, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.19
Upside: +5,826.72%
Sarepta Therapeutics
May 14, 2024
Upgrades: Outperform
Price Target: $180
Current: $122.68
Upside: +46.72%
Gain Therapeutics
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $2.23
Upside: +303.59%
Apr 19, 2024
Maintains: Outperform
Price Target: $105
Current: $90.56
Upside: +15.95%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $5.58
Upside: +617.49%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $17.64
Upside: +24.75%
Sep 13, 2023
Maintains: Outperform
Price Target: $31 → $16
Current: $4.28
Upside: +273.83%
Aug 21, 2023
Maintains: Outperform
Price Target: $950 → $1,050
Current: $841.88
Upside: +24.72%
Apr 4, 2023
Downgrades: Perform
Price Target: n/a
Current: $1.49
Upside: -
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $1.16
Upside: +56,177.06%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $20.10
Upside: +49.25%